<qa>  How many doses of DCs will be evaluated for safety and immune system response?Patients will be randomized to receive either intravenous or subcutaneous administration of HIV antigen expressing DCs. Each subject will receive two administrations of mature DCs given 3 weeks apart. Subjects will be followed weekly for 8 weeks, then at Weeks 12, 16, 24, 36, and 48. Two doses of DCs will be evaluated low dose: 1-3 million cells; high dose: 5-10 million cells for safety and immune system response. 